Compare Quanta Services Inc (PWR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Sanofi SA — how do they compare? Quanta Services Inc trades at $695.79 (market cap $103.03B), while Sanofi SA trades at $40.11 (market cap $95.18B). The key difference: Quanta Services Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Sanofi SA for 94 Days on average.
| PWR | SNY | |
|---|---|---|
Market Cap | $103.03B | $95.18B |
Volume | 977,892 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $785.24 | $52.34 |
52-Week Low | $412.21 | $39.51 |
Typical Hold Time | 62 Days | 94 Days |
Enterprise Value | $109.13B | $114.48B |
Dividend Yield | 0.06% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $701.07, down 2.57% on the day, but maintains a bullish technical stance with strong support near $690. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $802.08 implying significant upside.
The outlook for PWR is favorable, driven by a record $53B backlog and exposure to AI infrastructure spending. Key risks include execution challenges on large projects and rising debt levels. With 75% of analysts rating it a Buy and strong institutional support, the stock presents a growth opportunity, but investors should monitor cash flow trends and competitive pressures.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
